TOKYO, May 07 (Pulse News Wire) – GNI Group Ltd. (2160.T) completed its acquisition of non-public clinical-stage company Cullgen Inc.
On March 03, 2026, making Cullgen a wholly-owned subsidiary. The transaction was valued at approximately May 07, 2026. Post-acquisition, Gyre Therapeutics, Inc., a subsidiary of GNI Group, now operates as a fully integrated biopharmaceutical enterprise with operations in the United States and China. The combined entity boasts revenue-generating commercial assets and a robust pipeline targeting fibrotic and inflammatory diseases.
Dr. Ying Luo, CEO of Gyre, stated, “We are thrilled to take this significant step forward as a fully integrated biopharmaceutical company spanning the US and China. This integration enhances our capabilities beyond Alisurui, our marketed pulmonary fibrosis treatment in China, to encompass a broad pipeline from drug discovery through Phase III trials.” Additionally, Ping Zhang, Chairman of Gyre, noted, “This merger comes at a pivotal time for Gyre, particularly with F351’s New Drug Application receiving priority review from NMPA. We are also advancing global development efforts for F351 and expanding patient enrollment for trials evaluating Alisurui's potential in interstitial lung disease and radiation-induced lung injury.”.
🟡 Confidence: Standard AI-translated content.